RESUMEN
Low-grade adenosquamous carcinoma is a less frequent variant of metaplastic breast carcinoma, incidentally detected during screening and has an age distribution similar to other breast carcinomas. It shares characteristics with both benign and malignant carcinomas: its mammographic and sonographic features are therefore nonspecific. Breast conserving surgery with adjuvant radiation therapy is currently the preferred therapeutic approach. The aim of this review is to describe the imaging and clinical features of low-grade adenosquamous carcinoma for appropriate identification and diagnosis. The associated pitfalls, histopathologic and epidemiologic factors, natural course, and management of low-grade adenosquamous carcinoma are also discussed.
RESUMEN
As informações vindas de outras nações já evidenciavam que, quando a covid-19 chegasse ao Brasil, grandes desafios seriam enfrentados. Como estratégia de resposta aos pares, o Cremesp deu início às aulas virtuais no assunto, em um momento em que as lives ainda nem estavam tão popularizadas, além de produzir textos em seus veículos tradicionais e novo hotsite específico. O material ficou tão completo que deu origem a esta publicação, disponibilizada para download, para que os colegs possam imprimir e ter como material de apoio fácil, no momento em que estiverem em seus consultórios e plantões nos hospitais, sem a necessidade de consultar o smartfone, tablet ou computador. A publicação claro é inacabada, pois dados sobre Sars-CoV-2 surgem e mudam a todo o momento com novos estudos.
Asunto(s)
Humanos , Equipo de Protección Personal/efectos adversos , Prueba Serológica para COVID-19 , SARS-CoV-2/inmunología , COVID-19/prevención & control , Tratamiento Farmacológico de COVID-19 , Cuidados Paliativos , Respiración Artificial , Enfermedades de la Piel , Ivermectina/uso terapéutico , Brasil/epidemiología , Cloroquina/uso terapéutico , Lopinavir/uso terapéutico , COVID-19/psicología , Anticuerpos Monoclonales/uso terapéutico , Antiparasitarios/uso terapéuticoRESUMEN
BACKGROUND: Validation of digital whole slide images is crucial to ensure that diagnostic performance is at least equivalent to that of glass slides and light microscopy. The College of American Pathologists Pathology and Laboratory Quality Center recently developed recommendations for internal digital pathology system validation. Following these guidelines we sought to validate the performance of a digital approach for routine diagnosis by using an iPad and digital control widescreen-assisted workstation through a pilot study. METHODS: From January 2014, 61 histopathological slides were scanned by ScanScope Digital Slides Scanner (Aperio, Vista, CA). Two independent pathologists performed diagnosis on virtual slides in front of a widescreen by using two computer devices (ImageScope viewing software) located to different Health Institutions (AOUI Verona) connected by local network and a remote image server using an iPad tablet (Aperio, Vista, CA), after uploading the Citrix receiver for iPad. Quality indicators related to image characters and work-flow of the e-health cockpit enterprise system were scored based on subjective (high vs poor) perception. The images were re-evaluated two weeks apart. RESULTS: The whole glass slides encountered 10 liver: hepatocarcinoma, 10 renal carcinoma, 10 gastric carcinoma and 10 prostate biopsies: adenocarcinoma, 5 excisional skin biopsies: melanoma, 5 lymph-nodes: lymphoma. 6 immuno- and 5 special stains were available for intra- and internet remote viewing. Scan times averaged two minutes and 54 seconds per slide (standard deviation 2 minutes 34 seconds). Megabytes ranged from 256 to 680 (mean 390) per slide storage. Reliance on glass slide, image quality (resolution and color fidelity), slide navigation time, simultaneous viewers in geographically remote locations were considered of high performance score. Side by side comparisons between diagnosis performed on tissue glass slides versus widescreen were excellent showing an almost perfect concordance (0.81, kappa index). CONCLUSIONS: We validated our institutional digital pathology system for routine diagnostic facing with whole slide images in a cockpit enterprise digital system or iPad tablet. Computer widescreens are better for diagnosing scanned glass slide that iPad. For urgent requests, iPad may be used. Legal aspects have to be soon faced with to permit the clinical use of this technology in a manner that does not compromise patient care.
Asunto(s)
Interpretación de Imagen Asistida por Computador , Procesamiento de Imagen Asistido por Computador , Neoplasias/patología , Patología Clínica/métodos , Biopsia , Hospitales Universitarios , Humanos , Masculino , Microscopía , Proyectos Piloto , Guías de Práctica Clínica como Asunto , Sociedades Médicas , Programas Informáticos , Estados Unidos , Flujo de TrabajoRESUMEN
Cancer of unknown primary (CUP) represents a common and important clinical problem. There is evidence that most CUPs are metastases of carcinomas whose primary site cannot be recognized. Driven by the hypothesis that the knowledge of primary cancer could improve patient's prognosis, we investigated microRNA expression profiling as a tool for identifying the tissue of origin of metastases. We assessed microRNA expression from 101 formalin-fixed, paraffin-embedded (FFPE) samples from primary cancers and metastasis samples by using a microarray platform. Forty samples representing ten different cancer types were used for defining a cancer-type-specific microRNA signature, which was used for predicting primary sites of metastatic cancers. A 47-miRNA signature was identified and used to estimate tissue-of-origin probabilities for each sample. Overall, accuracy reached 100% for primary cancers and 78% for metastases in our cohort of samples. When the signature was applied to an independent published dataset of 170 samples, accuracy remained high: correct prediction was found within the first two options in 86% of the metastasis cases (first prediction was correct in 68% of cases). This signature was also applied to predict 16 CUPs. In this group, first predictions exhibited probabilities higher than 90% in most of the cases. These results establish that FFPE samples can be used to reveal the tissue of origin of metastatic cancers by using microRNA expression profiling and suggest that the approach, if applied, could provide strong indications for CUPs, whose correct diagnosis is presently undefined.